Document Type

Article

Publication Date

6-17-2019

Publication Title

The Journal of clinical investigation

Keywords

Animals; Docosahexaenoic Acids; Immunity, Cellular; Ketorolac; Male; Mice; Mice, Knockout; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasms, Experimental; Preoperative Care; T-Lymphocytes

Abstract

Cancer therapy is a double-edged sword, as surgery and chemotherapy can induce an inflammatory/immunosuppressive injury response that promotes dormancy escape and tumor recurrence. We hypothesized that these events could be altered by early blockade of the inflammatory cascade and/or by accelerating the resolution of inflammation. Preoperative, but not postoperative, administration of the nonsteroidal antiinflammatory drug ketorolac and/or resolvins, a family of specialized proresolving autacoid mediators, eliminated micrometastases in multiple tumor-resection models, resulting in long-term survival. Ketorolac unleashed anticancer T cell immunity that was augmented by immune checkpoint blockade, negated by adjuvant chemotherapy, and dependent on inhibition of the COX-1/thromboxane A2 (TXA2) pathway. Preoperative stimulation of inflammation resolution via resolvins (RvD2, RvD3, and RvD4) inhibited metastases and induced T cell responses. Ketorolac and resolvins exhibited synergistic antitumor activity and prevented surgery- or chemotherapy-induced dormancy escape. Thus, simultaneously blocking the ensuing proinflammatory response and activating endogenous resolution programs before surgery may eliminate micrometastases and reduce tumor recurrence.

Clinical Institute

Cancer

Department

Institute for Systems Biology

Department

Oncology

Download

PSJH Full Text

Share

COinS